Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2005 (Vol. 25, No. 3)

Center for Chemical Methodology and Library Development at Boston University

  • Overview of topic
  • Needs Expansion
Clever title, eh? Let’s call it CMLD here. A relatively new NIGMS-funded site at Boston University, CMLD focuses “on the discovery of new methodologies to produce novel chemical libraries of unprecedented complexity for biological screening.” Small molecule chemistry/biochemistry is hot, and CMLD is one place to stay abreast of this rapidly advancing field. Visitors to the site will notice the increasing use of the word “libraries” in conjunction with chemical collections, paralleling the similar use of the word by molecular biologists. Chemical libraries require (in some cases) novel stereo-controlled synthesis methods and these too are a part of the project. Access to protocols requires registration, however. Other features of the site include a small collection of links and a section (small) of positions available. Hopefully CMLD will expand soon.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »